The list of essential drugs will be introduced next year
2021-06-19 11:05:01
More than two years after the implementation, the call for the adjustment of the national essential medicine system has been on the rise. The primary change is the list of basic medicines that are not enough and part of the low-priced medicines are regularly out of stock.
At the press conference of the Ministry of Health recently, Zheng Hong, director-general of the Department of Drug Administration of the Ministry of Health, announced the news of the adjustment of the basic drug catalog. "It should be said that the adjustment of the basic drug list has already been placed before us. The latest cannot be later than next year," said Zheng Hong.
"Overall" replaces "primary version"
When the list of base medicines was established in 2009, the Ministry of Health first introduced a grass-roots version covering 307 varieties, and allowed local additions to be made according to actual conditions. However, in the course of using the grass-roots version of the list of basic medicines, all local hospitals reported relatively few varieties and relatively simple dosage forms, which could not meet the needs of basic medicines everywhere.
Zheng Hong revealed that the Ministry of Health will fully investigate the use of basic medicines in various places and fully absorb relevant experience in the pilot reforms of public hospitals. In particular, it should pay attention to the disease-based payment and total amount prepayments to be carried out in various places, and the clinical pathway should be well connected. Some medications in public health programs are linked. "Therefore, this list should be a whole, and it should increase in the number of varieties and in the dosage form."
However, so far, the country-wide drug-based system has not yet been promoted in secondary hospitals or above, and the major hospital-based drug list has not yet been established. Therefore, judging from the current information, this "total version" has a lot to cover primary hospitals and secondary hospitals.
According to Yu Mingde, president of the China Association of Chinese Medicine (600056, the stock) Enterprise Management Association, local medicines are currently not enough to reflect the use of basic drugs, but there has been a phenomenon of blind additions everywhere, the main reason for this contradiction is the lack of "basic medical disease directory" Therefore, the adjustment of the base medicine list must be combined with the establishment of the “Basic Medical Diseases Catalogue†to determine the list of required medicines according to the basic medical disease list.
U.S. UBS Securities Pharmaceutical Industry Analyst Ji Xu I told the “First Financial Daily†reporter that the market for basic drugs is currently less than 10% of the entire domestic drug market, so once the list of base drugs is adjusted, the impact on the pharmaceutical industry is not significant, but For pharmaceutical companies dominated by basic pharmaceutical products, the impact is relatively large, such as North China Pharmaceutical (600812, stock bar), Shiyao Group, Kelun Pharmaceutical (002422, stocks) and so on.
The unified pricing mechanism is difficult to produce
Not long ago, a clinically used essential protamine injection had appeared nationwide out of stock because the price was too low and there was no profit. In the base drugs, there are also some commonly used drugs such as compound reserpine flat films, which are tightly supplied due to low prices and supply breakdown of raw material medicines. The “spent curse†of low-priced drugs has frequently appeared.
Yu Mingde said that at present, the prices of basic drug products are confusing, and some of the drugs are often out of stock, which is the scourge of provincial bid invitations for the “lowest bidâ€.
Based on this, the new base drug pricing mechanism is also brewing. In August, some large corporations received internal consultation documents from the National Development and Reform Commission. The National Development and Reform Commission intends to uniformly set prices for 30 base pharmaceutical products and 11 Chinese proprietary Chinese medicines. Local bidding and procurement will no longer attract prices, and only hire manufacturers.
In the past two or three months, the unified pricing policy for basic drugs has not yet been introduced. Our reporter was informed that the National Development and Reform Commission for the unified pricing of basic drugs has not yet had a specific framework, including the selection criteria for unified pricing products, the number of varieties, the pricing level, how to link up with the existing drug-based policies, and whether the fixed-point production has been established. opinion.
From the industry point of view, due to the degree of perfection of the industrial chain, product mix, scale of production, and production costs, pharmaceutical companies have different demands for unified pricing. "Brand companies want to set a high price, so that there will be enough profit to produce and supply, but SMEs want to lower prices so that they have a low price advantage," a senior industry source told reporters.
At the press conference of the Ministry of Health recently, Zheng Hong, director-general of the Department of Drug Administration of the Ministry of Health, announced the news of the adjustment of the basic drug catalog. "It should be said that the adjustment of the basic drug list has already been placed before us. The latest cannot be later than next year," said Zheng Hong.
"Overall" replaces "primary version"
When the list of base medicines was established in 2009, the Ministry of Health first introduced a grass-roots version covering 307 varieties, and allowed local additions to be made according to actual conditions. However, in the course of using the grass-roots version of the list of basic medicines, all local hospitals reported relatively few varieties and relatively simple dosage forms, which could not meet the needs of basic medicines everywhere.
Zheng Hong revealed that the Ministry of Health will fully investigate the use of basic medicines in various places and fully absorb relevant experience in the pilot reforms of public hospitals. In particular, it should pay attention to the disease-based payment and total amount prepayments to be carried out in various places, and the clinical pathway should be well connected. Some medications in public health programs are linked. "Therefore, this list should be a whole, and it should increase in the number of varieties and in the dosage form."
However, so far, the country-wide drug-based system has not yet been promoted in secondary hospitals or above, and the major hospital-based drug list has not yet been established. Therefore, judging from the current information, this "total version" has a lot to cover primary hospitals and secondary hospitals.
According to Yu Mingde, president of the China Association of Chinese Medicine (600056, the stock) Enterprise Management Association, local medicines are currently not enough to reflect the use of basic drugs, but there has been a phenomenon of blind additions everywhere, the main reason for this contradiction is the lack of "basic medical disease directory" Therefore, the adjustment of the base medicine list must be combined with the establishment of the “Basic Medical Diseases Catalogue†to determine the list of required medicines according to the basic medical disease list.
U.S. UBS Securities Pharmaceutical Industry Analyst Ji Xu I told the “First Financial Daily†reporter that the market for basic drugs is currently less than 10% of the entire domestic drug market, so once the list of base drugs is adjusted, the impact on the pharmaceutical industry is not significant, but For pharmaceutical companies dominated by basic pharmaceutical products, the impact is relatively large, such as North China Pharmaceutical (600812, stock bar), Shiyao Group, Kelun Pharmaceutical (002422, stocks) and so on.
The unified pricing mechanism is difficult to produce
Not long ago, a clinically used essential protamine injection had appeared nationwide out of stock because the price was too low and there was no profit. In the base drugs, there are also some commonly used drugs such as compound reserpine flat films, which are tightly supplied due to low prices and supply breakdown of raw material medicines. The “spent curse†of low-priced drugs has frequently appeared.
Yu Mingde said that at present, the prices of basic drug products are confusing, and some of the drugs are often out of stock, which is the scourge of provincial bid invitations for the “lowest bidâ€.
Based on this, the new base drug pricing mechanism is also brewing. In August, some large corporations received internal consultation documents from the National Development and Reform Commission. The National Development and Reform Commission intends to uniformly set prices for 30 base pharmaceutical products and 11 Chinese proprietary Chinese medicines. Local bidding and procurement will no longer attract prices, and only hire manufacturers.
In the past two or three months, the unified pricing policy for basic drugs has not yet been introduced. Our reporter was informed that the National Development and Reform Commission for the unified pricing of basic drugs has not yet had a specific framework, including the selection criteria for unified pricing products, the number of varieties, the pricing level, how to link up with the existing drug-based policies, and whether the fixed-point production has been established. opinion.
From the industry point of view, due to the degree of perfection of the industrial chain, product mix, scale of production, and production costs, pharmaceutical companies have different demands for unified pricing. "Brand companies want to set a high price, so that there will be enough profit to produce and supply, but SMEs want to lower prices so that they have a low price advantage," a senior industry source told reporters.
Ningbo Wellway Optoelectronic Technology Co.,Ltd , https://www.wellwayopto.com